FiercePharmaOriginal article
{"a":[{"_":"Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial","$":{"href":"/pharma/bristol-lays-out-kras-med-krazatis-stumble-confirmatory-colorectal-cancer-trial","hreflang":"en"}}]}
RegulatorynegativeKrazatiNegative
AI Analysis
Summary
Bristol Myers Squibb's KRAS G12C inhibitor Krazati has encountered a major setback in its confirmatory colorectal cancer trial, potentially jeopardizing the conversion of its two accelerated approvals to traditional FDA approvals.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Stumble in confirmatory colorectal cancer trial for KRAS G12C inhibitor Krazati
Importance:7/10
Sentiment:
-0.70
KRASoncologyaccelerated approvalconfirmatory trialcolorectal cancer
Related Companies
Read the original article
Published by FiercePharma on July 7, 2026 10:26 AM